Grossman Wins 2025 Transatlantic Alliance Award in Endocrinology
Marc Y. Donath, MD, Appointed to Olatec’s Clinical Advisory Board
Marc Y. Donath, MD, medical director of the Diabetes Centre at the University Hospital Montreal, Canada, and chief physician in Endocrinology, Diabetes, and Metabolism at the University of Basel, Switzerland, has joined Olatec Therapeutics, Inc.’s Clinical Advisory Board (CAB). Donath, an immuno-endocrinologist, is globally recognized for his pioneering contributions to immunometabolism, particularly his discovery of...
The Endocrine Society’s 2025 Outstanding Mentor Laureate Award recipient Ellen Seely, MD, mentors both early-career endocrinologists as well as peers both in the U.S. and abroad. She discusses this unique arrangement as well as the excitement she feels when previous mentees become her research colleagues. For Ellen Seely, MD, mentoring is a rewarding, reciprocal relationship...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Olfactive Biosolutions Granted Third Dual GLP-1 / GIP Patent to Repurpose Food Molecules for Weight Management and Blood Sugar Regulation Olfactive Biosolutions was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in U.S. patent US 12,171,727...
HSS Names Matthew Drake, MD, PhD, Chief of Endocrinology and Metabolic Bone Service
Hospital for Special Surgery (HSS) announced the appointment of Matthew T. Drake, MD, PhD, as chief of the Division of Endocrinology and director of the Metabolic Bone Service. Drake has been a consultant in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition at the Mayo Clinic in Rochester, Minn., since 2007. He assumed a dual role...
Researchers have provided vital insights into social determinants such as government support, stable housing, and employment opportunities on postpartum health among Louisiana mothers during stressful periods including COVID-19, hurricanes, and the infant formula shortage. The study, “The role of government assistance, housing, and employment on postpartum maternal health across income and race: a mixed methods...
New CAH Treatment for Children and Adults Receives FDA Approval
In December, the U.S. Food and Drug Administration (FDA) approved crinecerfont capsules and oral solution adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). Crinecerfont is a selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that directly...
Elizabeth Pearce, MD, MSc, discusses her ENDO 2024 presentation, which found that exposure to some endocrine-disrupting chemicals that harm the thyroid gland has increased over the past 20 years among U.S. women of childbearing age and pregnant women, especially among those with lower social and economic status. Elizabeth Pearce, MD, MSc, of the Boston University...